PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 06: FIVE FORCES ANALYSIS • Bargaining power of suppliers • Bargaining power of buyers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY TYPE • Overview • Comparison by type • DPP4 inhibitor – Market size and forecast 2017-2022 • GLP-1 agonist – Market size and forecast 2017-2022 • SGLT2 inhibitor – Market size and forecast 2017-2022 • Others – Market size and forecast 2017-2022 • Market opportunity by type PART 08: CUSTOMER LANDSCAPE PART 09: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Key leading countries • Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS • Innovations in therapies • Strategic alliances between vendors • Increasing demand for combination drugs PART 13: VENDOR LANDSCAPE • Overview • Landscape disruption PART 14: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AstraZeneca • Eli Lilly • Merck • Novo Nordisk • Sanofi PART 15: APPENDIX • List of abbreviations Exhibit 01: Parent market Exhibit 02: Global diabetes therapeutics market: Segments Exhibit 03: Market characteristics Exhibit 04: Global non-insulin diabetes therapeutics market: Segments Exhibit 05: Market definition: Inclusions and exclusions checklist Exhibit 06: Market size 2017 Exhibit 07: Validation techniques employed for market sizing 2017 Exhibit 08: Global non-insulin diabetes therapeutics market 2017-2022 ($ millions) Exhibit 09: Global non-insulin diabetes therapeutics market: Year-over-year growth 2018-2022 (%) Exhibit 10: Five forces analysis 2017 Exhibit 11: Five forces analysis 2022 Exhibit 12: Bargaining power of suppliers Exhibit 13: Bargaining power of buyers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition: Five forces 2017 Exhibit 18: Segmentation by type: Market share 2017-2022 (%) Exhibit 19: Comparison by type Exhibit 20: DPP4 inhibitor 2017-2022 ($ millions) Exhibit 21: DPP4 inhibitor: Year-over-year growth 2018-2022 (%) Exhibit 22: GLP-1 agonist 2017-2022 ($ millions) Exhibit 23: GLP-1 agonist: Year-over-year growth 2018-2022 (%) Exhibit 24: SGLT2 inhibitor 2017-2022 ($ millions) Exhibit 25: SGLT2 inhibitor: Year-over-year growth 2018-2022 (%) Exhibit 26: Others 2017-2022 ($ millions) Exhibit 27: Others: Year-over-year growth 2018-2022 (%) Exhibit 28: Market opportunity by type Exhibit 29: Customer landscape Exhibit 30: Segmentation by geography: Market share 2017-2022 (%) Exhibit 31: Regional comparison Exhibit 32: Americas 2017-2022 ($ millions) Exhibit 33: Americas: Year-over-year growth 2018-2022 (%) Exhibit 34: EMEA 2017-2022 ($ millions) Exhibit 35: EMEA: Year-over-year growth 2018-2022 (%) Exhibit 36: APAC 2017-2022 ($ millions) Exhibit 37: APAC: Year-over-year growth 2018-2022 (%) Exhibit 38: Key leading countries Exhibit 39: Market opportunity Exhibit 40: Proportion of people aged 20-79 with diabetes 2015 Exhibit 41: Vendor landscape Exhibit 42: Landscape disruption Exhibit 43: Vendors covered Exhibit 44: Vendor classification Exhibit 45: Market positioning of vendors Exhibit 46: AstraZeneca: Overview Exhibit 47: AstraZeneca: Business segments Exhibit 48: AstraZeneca: Organizational developments Exhibit 49: AstraZeneca: Geographic focus Exhibit 50: AstraZeneca: Key offerings Exhibit 51: Eli Lilly: Overview Exhibit 52: Eli Lilly: Business segments Exhibit 53: Eli Lilly: Organizational developments Exhibit 54: Eli Lilly: Geographic focus Exhibit 55: Eli Lilly: Key offerings Exhibit 56: Merck: Overview Exhibit 57: Merck: Business segments Exhibit 58: Merck: Organizational developments Exhibit 59: Merck: Geographic focus Exhibit 60: Merck: Key offerings Exhibit 61: Novo Nordisk: Overview Exhibit 62: Novo Nordisk: Business segments Exhibit 63: Novo Nordisk: Organizational developments Exhibit 64: Novo Nordisk: Geographic focus Exhibit 65: Novo Nordisk: Key offerings Exhibit 66: Sanofi: Overview Exhibit 67: Sanofi: Business segments Exhibit 68: Sanofi: Organizational developments Exhibit 69: Sanofi: Geographic focus Exhibit 70: Sanofi: Key offerings

AstraZeneca, Eli Lilly, Merck, Novo Nordisk, and Sanofi.